Loading
A phase 1/2 trial of CAPOX, Capecitabine, Paclitaxel / nab-paclitaxel in metastatic cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., now recruiting.
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04495296 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 320 participants planned, started 2020-08-13 and due to reach its primary completion in 2026-06-25. Interventions recorded: TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine. Conditions listed: Advanced Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TST001, Transcenta, Gemcitabine, Metastatic cancer (cancer that has spread).
Shares CAPOX (capecitabine, oxaliplatin), Capecitabine, Nivolumab, Metastatic cancer (cancer that has spread).
Shares CAPOX (capecitabine, oxaliplatin), Capecitabine, Gemcitabine.
Shares CAPOX (capecitabine, oxaliplatin), Nivolumab, Metastatic cancer (cancer that has spread).
Shares CAPOX (capecitabine, oxaliplatin), Capecitabine, Gemcitabine.
Shares CAPOX (capecitabine, oxaliplatin), Paclitaxel / nab-paclitaxel, Gemcitabine.
Shares CAPOX (capecitabine, oxaliplatin), Paclitaxel / nab-paclitaxel, Gemcitabine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/